VTRS Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 2.53% compared to Viatris's net margin of 11.12%. Viatris's return on equity of -4.39% beat Boston Scientific's return on equity of 8.91%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.77%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 9.36%. Given that Boston Scientific has higher upside potential than Viatris, analysts believe Boston Scientific is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.85%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Viatris's is not.

Viatris quarterly revenues are $3.8B, which are smaller than Boston Scientific quarterly revenues of $4.2B. Viatris's net income of $94.8M is lower than Boston Scientific's net income of $468M. Notably, Viatris's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 8.45x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of 2.53% compared to Viatris's net margin of -3703.49%. Viatris's return on equity of -4.39% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.77%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 365.48%. Given that Lexicon Pharmaceuticals has higher upside potential than Viatris, analysts believe Lexicon Pharmaceuticals is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.85%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Viatris's net income of $94.8M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Viatris's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 43.00x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.53% compared to Viatris's net margin of 0.7%. Viatris's return on equity of -4.39% beat Moderna's return on equity of -17.44%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.77%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.87%. Given that Moderna has higher upside potential than Viatris, analysts believe Moderna is more attractive than Viatris.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.85%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Moderna quarterly revenues of $1.9B. Viatris's net income of $94.8M is higher than Moderna's net income of $13M. Notably, Viatris's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 3.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 2.53% compared to Viatris's net margin of 14.25%. Viatris's return on equity of -4.39% beat Insulet's return on equity of 49.55%.

Viatris has a consensus price target of --, signalling upside risk potential of 7.77%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 7.74%. Given that Viatris has higher upside potential than Insulet, analysts believe Viatris is more attractive than Insulet.

Viatris has a beta of 0.964, which suggesting that the stock is 3.557% less volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 3.85%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays 1052.29% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.8B, which are larger than Insulet quarterly revenues of $543.9M. Viatris's net income of $94.8M is higher than Insulet's net income of $77.5M. Notably, Viatris's price-to-earnings ratio is -- while Insulet's PE ratio is 45.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 1.00x versus 10.21x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.